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ABSTRACT
Introduction: Nearly every individual with 
schizophrenia is affected by cognitive decline. 
The aim of this literature review was to: (a) 
describe the humanistic burden of cognitive 
impairment associated with schizophrenia 
(CIAS); (b) develop a conceptual model that 
depicts the signs and symptoms of CIAS along 
with key concepts important to patients; and 
(c) consider the adequacy of potential patient-
reported outcome (PRO) instruments for 
assessing future treatments.
Methods: The following electronic databases 
were searched for articles published between 
January 1999 and November 2009 related to 
CIAS and PROs, or cost of illness: Medline; 
Embase; PsycINFO; the Health Economic 
Evaluation Database; and the National Health 
Service Economic Evaluation Database and 
Health Technology Assessment databases at 
the Centre for Reviews and Dissemination, 
University of York.
Results: The literature search revealed 
3950 abstracts, of which 101 articles were reviewed 
in detail. Cognitive functions affected include 
memory, attention/concentration, problem 
solving, learning, executive function, processing 
speed, and social cognition. Cognitive impairment 
impacts the ability of individuals to carry out 
activities of daily living, work productively, 
function socially, and adhere to treatment. 
These effects have economic ramifications 
through increased direct and indirect costs 
associated with the treatment of schizophrenia. 
The literature revealed 39 PRO instruments that 
have been used to assess functioning. However, 
no single instrument captures all key concepts of 
importance to patients with schizophrenia.
Conclusion: The significant burden from CIAS 
for patients and society has implications for 
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designing future treatments and health strategies 
to improve functional outcomes.
Keywords: burden; cognitive impairment 
associated with schizophrenia; conceptual 
model; cost; humanistic; patient reported 
outcome; schizophrenia
INTRODUCTION
Schizophrenia is a serious mental disorder 
affecting approximately 1% of the US 
population [1] and 24 million people 
worldwide [2]. It is characterized by the 
occurrence of positive symptoms [3], such 
as hallucinations or delusions [4], and 
negative symptoms [3], such as avolition [5], 
affective flattening, and social withdrawal [6]. 
Though schizophrenia affects a relatively 
small proportion of the population, it incurs 
substantial individual, societal, and healthcare 
costs [7,8].
Cognitive deficits are not yet included 
in the diagnostic criteria for schizophrenia, 
but are considered a core feature of 
schizophrenia symptomatology [9,10]. While 
neuropsychological impairment may not be 
present in all patients with schizophrenia [11], 
almost all patients with schizophrenia display 
some cognitive impairment in comparison with 
healthy controls [12]. Cognitive impairments 
are often fully developed when patients 
present with a first episode of illness [13,14]. 
Impairment occurs in most aspects of cognition, 
including attention, verbal learning and 
memory, secondary memory, working memory, 
and executive functions [10,15,16]. Indeed, 
cognitive impairments can reach two standard 
deviations below the normal mean [10]. These 
impairments are not the result of positive 
or negative symptoms, or accounted for by 
motivational deficits [17]. Furthermore, in most 
cases, cognitive impairments do not worsen or 
improve with illness progression [17].
While cognitive deficits appear to be 
strong predictors of functional outcome [9], 
currently there is no US Food and Drug 
Administration (FDA) or European Medicines 
Agency (EMA) approved treatment targeting 
cognitive impairment associated with 
schizophrenia (CIAS). Treatments available 
for schizophrenia include typical and atypical 
antipsychotics, which predominantly target 
the positive symptoms of schizophrenia 
[18]. Despite the availability of antipsychotic 
medications, patients with schizophrenia 
are often unsuccessful in re-entering the 
community [19] and treatments do not appear 
to improve cognitive function beyond practice 
effects [20,21]. Therefore, treatments for 
cognitive impairment have been identified as 
an unmet need [22].
In an effort to improve functional outcomes 
for patients with schizophrenia, pharmacological 
research has focused on the improvement of 
cognitive deficits [23]. Improving patients’ 
treatment experience is also a focus of the US 
National Institute of Mental Health (NIMH). 
The NIMH established the Measurement and 
Treatment Response to Improve Cognition in 
Schizophrenia (MATRICS), an academic/industry 
partnership.
A primary goal of the MATRICS was to 
decide on appropriate methods for evaluating 
new drugs [19]. The MATRICS Consensus 
Cognitive Battery (MCCB) was designed 
to provide new conventions for evaluating 
cognitive deficits in schizophrenia and aid in 
measuring treatment-related changes [24]. Seven 
independent cognitive domains were included 
in the MCCB: speed of processing, attention/
vigilance, working memory, verbal learning and 
memory, visual learning and memory, reasoning 
and problem solving (executive functioning), 
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and social cognition [19]. The MCCB consists 
of 10 cognitive tests designed to assess each 
domain [24].
C l in i c i an - repor ted  outcomes  and 
performance on cognitive tasks are important 
in assessing patient prognosis and treatment 
efficacy. However, the patient perspective can 
also provide valuable insights [25,26] and may 
provide a link between cognitive performance 
and the patient’s actual level of real-world 
functioning [27]. To date, patient-reported 
outcomes (PRO) instruments have not been 
evaluated for assessing treatments for CIAS. 
To assess PRO instruments and, specifically, 
comprehensiveness of the concepts measured, 
it is important to understand the humanistic 
burden of CIAS, which has not yet been 
summarized.
Specifically, there is no conceptual model of 
the burden of CIAS on patients’ lives. Conceptual 
models summarize the key concepts related to an 
illness or condition that could be measured with 
a PRO instrument. A conceptual model provides 
a visual representation of key concepts important 
to patients and they relate to each other [28]. 
The model compartmentalizes potential causes, 
consequences, and signs and symptoms of the 
disease. The purpose of a conceptual model is to 
provide a basis for assessing PRO questionnaires. 
For example, to adequately measure the impact 
of CIAS, a PRO questionnaire should capture all 
concepts of importance to patients.
Furthermore, various PRO questionnaires 
have been used in studies with patients with 
schizophrenia (eg, the Social Functioning 
Scale [SFS]) [29]. However, their suitability 
have not been thoroughly considered in light 
of the nature of schizophrenia guidelines, such 
as the MATRICS initiative [19,30], or the FDA-
published PRO guidelines [31].
This literature review explores studies in 
schizophrenia related to cognitive impairment, 
PRO, or cost with the view to: (a) describe 
the humanistic burden of CIAS; (b) develop 
a conceptual model of CIAS to identify key 
concepts important to patients; and (c) consider 




Using guidelines defined by the University of 
York National Health Service (NHS) Centre 
for Reviews & Dissemination (CRD) [32], a 
search strategy was developed. Three electronic 
databases (Medline, PsycINFO, and Embase) 
were searched for articles published between 
January 1999 and November 2009. The terms 
used are provided in Table 1.
Economic Database Searches
Using the cost terms (Table 1), the following 
databases were searched: Health Economic 
Evaluation Database (HEED); and the NHS 
Economic Evaluation Database (NHS-EED) and 
Health Technology Assessment (HTA) databases 
at the CRD, University of York.
National Institute of Mental Health (US) 
Review
Key publications relating to the NIMH MATRICS 
initiative were also reviewed for information 
related to impaired cognition in schizophrenia 
and recommendations for measurement of 
cognitive function [19,22,24,27,30,33].
Inclusion and Exclusion Criteria
All titles and abstracts were screened for 
inclusion in the study by two researchers.
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To be included, abstracts had to contain a 
clinical and medication term, a cognition term, 
and at least one of the PRO or cost terms. Journal 
articles were limited to English language and 
human subjects. The selected studies contained 
keywords in the title or abstract. Studies were 
excluded only if the reviewers agreed that they 
did not fulfill the criteria.
Ranking Process
The selected studies were ranked according to 
whether relevant terms in the title/abstract 
were: (a) the focus of the article; (b) provided 
as secondary or exploratory to the focus of the 
article; or (c) mentioned in the background 
or the discussion. Only articles ranked 1 were 
included for further consideration.
Data Extraction
Data extraction tables were developed to extract 
information accurately on relevant features 
and results of the selected studies. The key 
components of the data extraction tables were 
general information relating to the authors, 
publication date, country of study, and reference, 
as well as specific information relating to the aims 
of the study, patient population, sample size, 
study design, treatments, cognitive impairment 
and PRO measurements, main PRO and cognitive 
impairment results, and key concepts to consider.
Development of Conceptual Model
Key concepts were identified from the published 
literature, with a particular focus on studies 
Table 1. Database search terms.
Clinical and medication terms Schizophrenia AND antipsychotic OR neuroleptics OR 
 acetylcholinesterase inhibitors OR modafinil OR memantine OR AND 
 nicotinic acetylcholine receptor agonist 
Cognition terms Cognitive improvement OR cognitive enhancement OR 
 cognitive function OR cognitive deficits OR neurocognitive deficits OR 
 executive function OR mental status OR cognitive capacity OR AND 
 cognitive assessment OR cognitive performance OR cognition OR 
 memory OR confusion OR concentration 
PRO term Health-related quality of life OR quality of life OR patient burden OR 
 patient impact OR self-care OR relationships OR family impact OR 
 functional status OR functional capacity OR functional performance OR 
 functional impairment OR psychosocial OR social functioning OR 
OR
 
 emotions* OR symptom* OR work OR activities of daily living OR 
 patient experience OR subjective experience OR qualitative 
Cost term Cost* OR cost of illness OR economic burden OR financial burden OR 
 economic impact OR spending on treatments OR resource use OR 
 hospitalization OR unmet need OR consumption of healthcare resources OR 
 productivity loss OR resource management OR absenteeism OR 
 expenditure OR emergency services OR outpatient services OR disability  
PRO=patient-reported outcome.
*Search for truncated term.
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reporting qualitative data from the patient 
perspective. Relationships between concepts 
were identified from reported results specifically 
relating to cognitive impairment.
PRO Instrument Evaluation Criteria
The PRO instruments identified were reviewed 
according to criteria outlined by the US FDA 
Guidance for Industry [31]:
•	 Conceptual framework: Documentation of 
a diagram that defines concepts measured by 
the instrument, relationships between items, 
domain (sub-concepts) and concept measured, 
and scores produced by a PRO instrument.
•	 Content validity: Extent to which the 
instrument measures the concepts of interest 
(ie, inclusion of items and domains that are 
appropriate and comprehensive relative to its 
intended measurement concept, population, 
and use).
•	 Psychometric properties: Elements that 
contribute to the statistical adequacy of 
an instrument, where relevant, in terms of 
reliability, construct validity, and ability to 
detect change.
•	 Characteristics: Number of items, mode of 
administration, response options, scoring, 
and recall period.
Instruments that had been used in ≥3 studies 




Fig. 1 shows the number of abstracts reviewed 
and the article selection process. The literature 
search revealed 3950 abstracts, of which 
101 articles were reviewed in detail.
Searches in main databases
(Medline, EMBASE, PsychInfo)

































PRO and cost article
Fig. 1. Article selection process. HEED=Health Economic Evaluation Database; HTA=Health Technology Assessment; 
NHS-EED=National Health Service Economic Evaluation Database; PRO=patient-reported outcome.
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Cognitive Impairment Associated with 
Schizophrenia
Cognitive functions appear to be impaired 
in patients with schizophrenia (Fig. 2). Some 
cognitive dysfunctions are present during 
childhood and early adolescence; thus, pre-
dating the onset of psychosis [15]. Furthermore, 
treatment with conventional antipsychotic 
medication may exacerbate impaired cognitive 
functioning [34,35].
Effects of Treatment on Cognitive 
Impairment Associated with Schizophrenia
Although evidence suggests that cognitive 
deficits are specific to schizophrenia 
itself and not a side effect of neuroleptic 
medication [10,15], cognitive functions 
may decline further as a side effect of typical 
antipsychotics [6,35]. These appear to have 
detrimental impact on cognition and functional 
outcomes [36]. While a lower dosage of some 
typical antipsychotics may reduce cognitive 
impairments and some atypical antipsychotic 
medications do not appear to worsen cognitive 
impairment, a significant improvement is 
not apparent. In addition, anticholinergic 
drugs, used as adjunctive treatment for 
extrapyramidal side effects, may also affect 
cognition, particularly memory [37]. Side effects 
can impact the patient’s attitude to medication 
and may be a cause of nonadherence to the 
medication regimen [38].
Humanistic Burden of Cognitive Impairment 
Associated with Schizophrenia
Cognitive impairment appears to have a 
significant impact upon patients’ lives; affecting 
activities of daily living [9], independent 
living [6,18], social functioning [16,39,40], 








•  Declarative memory
•  Working memory
Learning
Attention/concentration
Social cognition Processing speedVisuomotor speed
Executive function
Fig. 2. Cognitive functions impaired in patients with schizophrenia.
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Conceptual Model
Based on the literature, Fig. 4 [43-67] illustrates 
a conceptual model of CIAS. Positive, negative, 
and affective symptoms, as well as impaired 
cognitive functions and side effects of treatment 
contribute to the burden of schizophrenia. 
In addition, the impact may be influenced by 
psychosocial factors, such as social support and 
a relationship with healthcare professionals.
Using PRO Instruments to Measure the 
Impact of Cognitive Impairment Associated 
with Schizophrenia on Patients
From the articles reviewed, 39 different PRO 
instruments were identified. These included 
measures of health-related quality of life 
(HRQoL) (n=12), symptoms (n=8), functioning 
(n=7), subjective experience with treatment 
(n=4), activities of daily living (n=2), side effects 
(n=2), insight into schizophrenia (n=1), and 
sleep (n=1). The other two instruments measured 
aspects of personality or body image.
Table 2 indicates whether instruments were 
developed for use in patients with schizophrenia 
or for use in a range of disease areas and/or in 
general populations.
Economic Burden of Cognitive Impairment 
Associated with Schizophrenia
No publications were identified that focused 
on the economic burden of CIAS. The total 
economic burden of schizophrenia was reported 
to be up US$62 million; however, this varied 
considerably between countries (due to varying 
patient populations) and different methods of 
cost data collection and estimation [7,8,68-70]. 
The contributing factors to the economic 
burden of schizophrenia include direct costs 
(inpatient hospitalization, outpatient hospital 
care, drug costs, residential/social/day care, 
and community medical services) and indirect 
costs (carer burden, lost productivity, premature 
death, and criminal justice system). Drug costs, 
for either typical or atypical antipsychotics, 
represent less than a quarter of the direct 
costs of schizophrenia [8,70-76]. Inpatient 
costs account for the majority of the direct 
costs [71] of schizophrenia, driven largely 
by relapse and re-hospitalization of patients 
due to noncompliance with medication, 
leading to more frequent and severe 
episodes of psychosis [72,77]. Indirect costs,
and in particular lost productivity costs,




•  Problem solving
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Fig. 3. Impact of CIAS on patients with schizophrenia. CIAS=cognitive impairment associated with schizophrenia.
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schizophrenia [7,8,69,70,74,78]. Typically, only 
20% of patients with schizophrenia find paid 
employment and 80% are unable to return to 
work following the first episode of psychosis; 
even when paid employment is achieved, 
job tenure is a frequent problem for patients, 
who appear to fare worse in the workforce 
than patients with other mental disorders 
[78,79]. From the studies identified, it is not 
possible to determine which of these costs are 
directly attributable to cognitive impairment; 
however, studies have reported a link between 
cognitive functioning and employment in 
schizophrenia [42,79,80].
DISCUSSION
This review explored the impact of cognitive 
impairment on patients with schizophrenia, 
and presents preliminary findings. Additionally, 
a conceptual model was developed to illustrate 
the patient’s experience of cognitive impairment 
with the aim of improving our understanding 
of the concepts that are important to patients 
relative to their disease. Cognitive dysfunction 
is apparent in emotional, social, educational, 
functional, and occupational areas of patients’ 
everyday lives. Cognitive impairment is also 
a barrier to medication adherence (typically 
due to working and long-term memory 
difficulties) [59]. This can be problematic for 
the individual, worsening positive and negative 
symptomatology [34], and may lead to increased 
costs. Adequate diagnosis, management, and 
treatment of CIAS are required to improve the 
patient’s experience, and minimize the burden 
of illness for patients and society.
Schizophrenia is a costly psychiatric disorder 
to manage; the annual cost of an average patient 
with schizophrenia is reported to be significantly 
higher than other mental health conditions [8]. 
This review highlighted a paucity of evidence 
focusing on the economic burden of CIAS 
specifically. Cognitive functioning, more than 
positive or negative symptoms, is the major 
determinant of functional and employment-
related outcomes in schizophrenia [42,79,80]. 
As cognition is associated with employment 
outcomes [42,79,80] (and therefore loss of 
productivity), further research quantifying the 
direct and indirect costs of CIAS would be of 
great value.
New pharmacologic interventions are in 
development, and PRO instruments can be 
used to assess the impact of treatments on 
patient functioning in both clinical trials and 
clinical practice. Many studies rely on clinician 
assessment or experimental tasks to measure 
cognitive performance and patient functioning. 
However, there is a lack of research into the 
discrepancy between functional skills and 
what patients are actually able to do in the real 
world [9]. In addition, few clinical trials include 
a PRO as an endpoint, which could provide 
important insight about a patient’s ability to 
function and overall HRQoL. Depending on the 
severity of cognitive impairment and the stage 
of episode, patients with schizophrenia are able 
to self-rate their affective state of well-being 
and level of functioning [77,81]. However, the 
individual may be less aware of the severity of 
their illness and its impact on their functioning 
and, therefore, as cognition and insight 
improve, there may be a paradoxical decline in 
perceived HRQoL [43].
A number of PRO instruments have 
been used in studies with patients with 
schizophrenia. No single instrument captures 
all key concepts of importance to patients with 
schizophrenia, and the appropriateness of a 
PRO instrument should be considered in light 
of its development history, face and content 
validity, psychometric properties, and purpose 
for use [31]. Many of the instruments used 
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to assess patient functioning were developed 
in a general or nonschizophrenia patient 
population (eg, the Medical Outcomes Study 
Short Form [SF-36], Sickness Impact Profile [SIP], 
and Social Adjustment Scale [SAS] I and II). 
Consequently, concepts of importance may 
not have been adequately measured; this may 
affect the validity of results based upon these 
instruments. Furthermore, the schizophrenia-
specific instruments and those developed for a 
psychiatric population (eg, Heinrichs-Carpenter 
Quality of Life Scale and Social Behavior Scale 
[SBS]) rely on a clinician rating. A clinician 
or informant rating does not provide a direct 
report of patient experience; potentially leading 
to a discrepancy between the patient experience 
and data provided.
It is important to recognize the limitations 
of this review. The findings are based on 
studies published in English over the last 
10 years to capture only the most recent and 
up-to-date studies. The authors recognize that 
these inclusion criteria may have led to a bias 
in the results presented. There is a dearth of 
qualitative research with patients or caregivers 
that describe patients’ experiences of CIAS 
in depth. The conceptual model presented 
in this paper should, therefore, be used as an 
exploratory framework for further research 
into the real-world functioning of patients 
with schizophrenia. Only by exploring and 
documenting patient experiences can adequate 
and appropriate measurement tools be 
developed.
This literature review suggests there is a lack 
of adequate PRO instruments for measuring the 
burden of CIAS. Further research to confirm the 
impact of cognitive impairment on patients 
with schizophrenia would be necessary in order 
to modify or develop appropriate, valid PRO 
measures to assess new treatments targeting 
CIAS.
CONCLUSION
This review provides evidence that CIAS results 
in a significant burden for patients, healthcare 
systems, and society. Cognitive function may 
fluctuate throughout the course of illness, 
possibly exacerbated by current drug treatments 
and other psychosocial factors. The overall 
burden incurred suggests the need for treatments 
that improve cognitive function while not 
interacting with existing treatments, and that 
have a favorable safety profile. Given the value of 
assessing patient functioning in clinical trials and 
clinical practice, it is important that appropriate, 
valid PRO instruments are developed or identified 
to assess treatments targeting CIAS.
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